What Will Happen to Achillion Pharmaceuticals Incorporated (NASDAQ:ACHN) Next? The Stock Has Decline in Shorts

June 20, 2017 - By Vivian Currie

 What Will Happen to Achillion Pharmaceuticals Incorporated (NASDAQ:ACHN) Next? The Stock Has Decline in Shorts

Investors sentiment decreased to 1.09 in Q4 2016. Its down 0.43, from 1.52 in 2016Q3. It fall, as 32 investors sold Achillion Pharmaceuticals, Inc. shares while 33 reduced holdings. 22 funds opened positions while 49 raised stakes. 97.41 million shares or 7.54% less from 105.36 million shares in 2016Q3 were reported.
Moreover, Nationwide Fund Advsrs has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 86,279 shares. State Street holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 5.12M shares. Dafna Ltd holds 0.71% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) or 196,500 shares. Vident Invest Advisory Ltd Liability Corp holds 84,625 shares or 0.04% of its portfolio. Manufacturers Life Ins The reported 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Renaissance Technologies Ltd Liability Corporation accumulated 945,189 shares or 0.01% of the stock. Doheny Asset Mgmt Ca holds 0.08% or 40,000 shares in its portfolio. Susquehanna Intl Group Limited Liability Partnership holds 125,828 shares or 0% of its portfolio. The New York-based Tower Research Cap Limited Liability Co (Trc) has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Moreover, Bb Biotech Ag has 0.2% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) or 2,980 shares. Principal Fincl Gp owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 21,507 shares. Blackrock Investment Ltd Liability Corp holds 435,720 shares. Tekla Management Lc, a Massachusetts-based fund reported 443,851 shares. Integral Derivatives Limited invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

The stock of Achillion Pharmaceuticals Incorporated (NASDAQ:ACHN) registered a decrease of 11.87% in short interest. ACHN’s total short interest was 9.25M shares in June as published by FINRA. Its down 11.87% from 10.50M shares, reported previously. With 1.09M shares average volume, it will take short sellers 9 days to cover their ACHN’s short positions. The short interest to Achillion Pharmaceuticals Incorporated’s float is 10.12%.

It closed at $4.37 lastly. It is down 47.61% since June 20, 2016 and is downtrending. It has underperformed by 64.31% the S&P500.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $617.26 million. The Firm is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. It currently has negative earnings. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 10 analysts covering Achillion Pharma (NASDAQ:ACHN), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Achillion Pharma had 17 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was downgraded by Leerink Swann on Friday, January 29 to “Market Perform”. The stock has “Hold” rating by Jefferies on Wednesday, September 9. Maxim Group maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Thursday, August 13. Maxim Group has “Buy” rating and $11 target. FBR Capital initiated Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Thursday, September 15. FBR Capital has “Outperform” rating and $16 target. The firm has “Outperform” rating by Leerink Swann given on Thursday, May 18. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Buy” rating by UBS on Tuesday, September 8. The rating was maintained by Chardan Capital Markets with “Sell” on Friday, September 23. The firm has “Outperform” rating by Wedbush given on Friday, September 23. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Sell” rating by Chardan Capital Markets on Thursday, July 14. Robert W. Baird upgraded the shares of ACHN in report on Friday, February 26 to “Outperform” rating.

More news for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) were recently published by: Prnewswire.com, which released: “Biotech Stocks on Investors’ Radar — Achillion Pharma, Acorda Therapeutics …” on May 26, 2017. Globenewswire.com‘s article titled: “Achillion to Present at the 2017 JMP Securities Life Sciences Conference” and published on June 15, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.